C008P: Belatacept Biosimilar, CTLA-4 Fc Fusion Protein

Catalog No.: C008P | **Product Name:** Belatacept Biosimilar

Belatacept Biosimilar. Nulojix biosimilar CHO stable cell line is available for licensing to manufacture the belatacept biosimilar protein. The research grade belatacept biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls and recombinant hIgG1 Fc proteins are available.

PRODUCT SPECIFICATIONS

Catalog No.	C008P
Product Name	Belatacept Biosimilar
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Nulojix, CTLA-4 Fc Fusion Protein
Summary	Recombinant protein composed of the extracellular domain of CTLA-4 fused with the Fc region of human immunoglobulin gamma 1 (hIgG1).
Source/Host	The belatacept biosimilar protein was produced in the Nulojix biosimilar CHO stable cell line.
Specificity/Sensitivity	The belatacept biosimilar protein specifically binds to the human CD80 (B7-1) with more avidity than to CD86 (B7-2).
Applications	Functional assays, and those assays for studying biological pathways affected by belatacept.
Form Of Antibody	0.2 μM filtered solution, pH 7.2 to 7.8, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The belatacept biosimilar protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Nulojix biosimilar CHO stable cell line is available for licensing to manufacture the belatacept biosimilar protein. The research grade belatacept biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls and recombinant hIgG1 Fc proteins are available.

REFERENCES & BACKGROUND

What is Belatacept biosimilar research grade? Belatacept (trade name Nulojix, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Belatacept differs from abatacept (trade name Orencia) by only 2 amino acids. The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation. Belatacept Biosimilar uses the same protein sequences as the therapeutic protein belatacept.